Member Info for mol42

Https://www.optibiotix-ir.com/docs/librariesprovider35/archive/results/interims-2024.pdf

released 27 Sep 2024

and to finish what martinu posted next paragraph

Whilst initial discussions and assessment are with specialist weight management clinics largely in London,

if these early findings are confirmed we will go direct to the pharmaceutical companies selling these

products to explore the potential of using SlimBiome, probably by a different name, as an adjuvant to

drug treatment.

mol

Pity you didn’t mention same in original post together with link

Never mind

mol

Link here fwiw

https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-sbtx/skinbiotherapeutics-shares/ownership

mol

@ 17.33 today

Topping all of this is the tiny amount of shares in issue, less those in safe hands.

Que?

Issued share capital: 228,435,909 Ordinary Shares of 1p nominal value.

The percentage of Ordinary Shares not being held in public hands is 17.1%.

with the definition being

For the purposes of UKLR 5.5.1R and UKLR 5.5.2R, shares are not held in public hands if they are:

(1) held, directly or indirectly, by:

(a) a director of the applicant or of any of its subsidiary undertakings;

(b) a person connected with a director of the applicant or of any of its subsidiary undertakings;

(c) the trustees of any employees’ share scheme or pension fund established for the benefit of any directors and employees of the applicant and its subsidiary undertakings;

(d) any person who, under any agreement, has a right to nominate a person to the board of directors of the applicant; or

(e) any person or persons in the same group or persons acting in concert who have an interest in 5% or more of the shares of the relevant class; or

(2) subject to a lock-up period of more than 180 calendar days.

Director Number Ordinary Shares %

Martin Hunt* 560,417 0.25%

Stuart John Ashman 276,804 0.12%

Manprit Randhawa 153,165 0.07%

Dr Cathy Prescott 181,112 0.08%

Danielle Bekker 43,750 0.02%

and

Significant Shareholders

As at 17 October 2024 significant shareholders that hold more than 3% of the share capital of SkinBioTherapeutics plc are detailed below:

Number Ordinary Shares %

OptiBiotix Health Plc 24,940,639 10.92%

Tyndall Investment Management 18,357,826 8.04%

Seneca Partners Limited 14,228,283 6.23%

David Brierwood 6,998,305 4.09%

The University of Manchester 8,000,000 3.50%

Unicorn Asset Management 7,894,737 3.46%

which i think Optibiotix holding at 17 October 2024 is included in that 17.1% as noted above and not the other 3% holders

and according to the concensus here opti continue to offload - so hardly safe

thus the vast majority of shares are held by those in public hands - especially retail investors - fickle lot they are

mol

And what's this all about?

https://find-and-update.company-information.service.gov.uk/company/OE008603

just thought I'd do a bit of follow up on our new non-exec director (albeit not noted on pbx website yet) and the interests registered in rns regarding him

mind we also still don't know what the subsidiary registered by steen back in time is all about or do we..........

was it to be the danish pbx once taken private - as he hoped?

no idea just speculating

mol

I haven’t listened to the broadcast yet and therefore unaware of any reference to dividends within same

I was clarifying my position re my response to Aquae’ post and in addition making bb aware of the potential future use of SP account

mol

The accumulated losses to Jun 23 are £11,122,943. The company can apply to the Court to use the credit on the Share premium account of £10,947,874 to substantially reduce the P and L deficit hence hopefully accelerating the day when we will have distributable reserves. As recently announced the audited figures to Jun 24 will be available next week with further movement on PL and SP accounts.

I was mentioning the tax losses in response to the cashflow post from aquae as they will continue to be available for carry forward against profits from the same trade hence postponing the cash outflow of corporation tax.

mol

Still here - still a shareholder - still haven't sold any

but

tick tock

all the same

bw all

mol

And a history of appointments and resignations all on more or less one page

right in our face

mol

And surely you will all note it is only him and SOH at opti ltd

mol

And I don't count Shiraz - the effect - as a person who should be a exec director of a plc or even a non-exec of a plc

albeit he is a director of optibiotix ltd as i 've noted before

https://find-and-update.company-information.service.gov.uk/company/07992608/filing-history

mol

Apparently TW is wondering if we need an FD

a legitimate question however

I am firmly in the appoint another executive director and one with not only business acumen but b.... to stand up to our CEO

who thinks this company is his personal fiefdom together his attendant concert party

it's not

mol

I would love to hear news of products containing SweetBiotix (tm) being sold. It would not be before time!!

not the only one methinks

bw

mol

5. Maintain the board as a well-functioning, balanced team led by the chair

The board members have a collective responsibility and legal obligation to promote the interests of the company, and are collectively responsible for defining corporate governance arrangements. Ultimate responsibility for the quality of, and approach to, corporate governance lies with the chair of the board.

The board (and any committees) should be provided with high quality information in a timely manner to facilitate proper assessment of the matters requiring a decision or insight.

The board should have an appropriate balance between executive and non-executive directors and should have at least two independent non-executive directors. Independence is a board judgement.

The board should be supported by committees (e.g. audit, remuneration, nomination) that have the necessary skills and knowledge to discharge their duties and responsibilities effectively. Directors must commit the time necessary to fulfil their roles.

The Board includes a balance of Executive and Non-Executive Directors.

The Board currently comprises 2 Executive and 2 Non-Executive Directors with an appropriate balance of sector, financial and public market skills and experience.

The board is comprised of:-

Neil Davidson

Sean Christie

Stephen O'Hara, CEO

Dr Sofia Kolyda

The directors' roles and responsibilities are shown on the website http://optibiotix.com/corporate/. The Board's activities are supported by Nomination, Audit and Remuneration Committees.

All the Directors have appropriate skills and experience for the roles they perform at the Company, including as members of Board Committees.

Directors are subject to re-election at least every three years in accordance with the articles of association.

The Company is satisfied that the current Board is sufficiently resourced to discharge its governance obligations on behalf of all stakeholders and will consider the requirement for additional Non-Executive Directors as the Company fulfils its growth objectives.

Note our only two exec Directors are Stephen and Sofia - and whilst our company is satisfied that the current Board is

sufficently resourced - I'm not and haven't been for some time (ie years) and have noted same on this bb in the past

mol

No not what you may be thinking

jees if only

but David Blain's appointment to Board as Graham Myers last day being 30 NOvember 2024 - i had great hopes for him but unfortunately only lasted exactly a year

04 Dec 2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023.

Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's £800m UK pension scheme.

Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support the focus on driving each business unit and the Group to profitability.

nevermind

23 October 2024

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara. Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

A star our non-exec chairman - don't you all think?

mol

I'll remind the bb of 27 Feb 2024 rns - included in which was

The Company has included SweetBiotix® in a finished product for a large global partner with a view for an upcoming launch. The Company hopes to see SweetBiotix® in an increasing number of products launched throughout 2024.

The Company has received preliminary forecasts from DSM-Firmenich, one of its SweetBiotix® partners, of >100,000 metric tonne per annum. Whilst a preliminary forecast it demonstrates the scale of intent and the size of the opportunity.

Stephen O’Hara, CEO of OptiBiotix Health plc said: “We are pleased to report substantial progress over the last 12 months with our first-generation products returning to sales growth, a number of well-known corporate partners reaching agreements (e.g Tata, Brenntag,) and launching new products with major brands (MuscleTech) in new channels. We are also pleased to see continued growth of online sales, particularly in China, and are looking to replicate this success in other territories, such as India. These all have the potential to bring in significant future revenues. With all parts of the business returning to strong growth and a pipeline of potential multi million pound deals in India and the USA, we are excited about the future.

“Finally, we are pleased with progress on SweetBiotix®, its first introduction into a finished product, and the scale of the opportunity forecast by DSM Firmenich. We believe we have a number of substantive opportunities, any one of which would be transformational for the Company and shareholders alike, and collectively change the future of the business.”

Our company continually hopes or expects or believes or has potential or demonstrates and has done since admission to aim

tick tock

mol

Oops meant to add after on this occasion - with net assets £795,611 and before with increase on PL

mol

And we don't seem to have dramatically overpaid on this occasion

with increase on P and L for year ending 2024 of £259,678 compared to our rns of £0.5m of EBITDA for the year ending 30 June 2024 - which isn't a million miles away after interest, tax, depreciation, amortisation and perhaps a dividend to shareholders

mol

Unaudited financial statements filed today

https://find-and-update.company-information.service.gov.uk/company/04557084/filing-history

I draw your attention to notes 9 and 10

at least HMRC enquiry liability finalised going forward and provision made

mol

Not slow in publishing her research, albeit with others, on her return to academia

https://www.researchgate.net/profile/Catherine-Oneill

this one caught my attention - albeit no specific reference to us

https://academic.oup.com/jambio/article/135/8/lxae181/7725828?login=false#478281065

mol